Neuroblastoma progress on many fronts: The neuroblastoma research symposium

Pediatric Blood and Cancer

Volumn 58, Issue 4, 2012, Pages 649-651

  Wylie, Luke ^a,b   Philpott, Anna ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Molecular biology of neuroblastoma; Neuroblastoma; Neuroblastoma biology

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANAPLASTIC LYMPHOMA KINASE; CASZ1 PROTEIN; CLUSTERIN; DNA TOPOISOMERASE INHIBITOR; GANGLIOSIDE GD2; MONOCLONAL ANTIBODY; MYCN PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PAIRED LIKE HOMEOBOX 2B PROTEIN; PROTEIN; RETINOIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL LINEAGE; CELL METABOLISM; CELL PROLIFERATION; CHROMOSOME ABERRATION; DNA DAMAGE; EPIGENETICS; GENE MUTATION; HUMAN; NEURAL CREST CELL; NEUROBLAST; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL;

BIOMEDICAL RESEARCH; CHILD; CHILD, PRESCHOOL; CONGRESSES AS TOPIC; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTORS;

EID: 84856937033     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23329     Document Type: Article

References (18)

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211.
2. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009; 27: 298-303.
3. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 2009; 27: 289-297.
4. Mosse YP, Laudenslager M, Khazi D, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004; 75: 727-730.
5. Dubreuil V, Hirsch MR, Pattyn A, et al. The Phox2b transcription factor coordinately regulates neuronal cell cycle exit and identity. Development 2000; 127: 5191-5201.
6. Dubreuil V, Hirsch MR, Jouve C, et al. The role of Phox2b in synchronizing pan-neuronal and type-specific aspects of neurogenesis. Development 2002; 129: 5241-5253.
7. Trochet D, Hong SJ, Lim JK, et al. Molecular consequences of PHOX2B missense, frameshift and alanine expansion mutations leading to autonomic dysfunction. Hum Mol Genet 2005; 14: 3697-3708.
8. Reiff T, Tsarovina K, Majdazari A, et al. Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons. J Neurosci 2010; 30: 905-915.
9. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935.
10. Lopez-Garcia C, Klein AM, Simons BD, et al. Intestinal stem cell replacement follows a pattern of neutral drift. Science 2010; 330: 822-825.
11. Hansford LM, McKee AE, Zhang L, et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007; 67: 11234-11243.
12. Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009; 8: 1579-1588.
13. Chayka O, Corvetta D, Dews M, et al. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst 2009; 101: 663-677.
14. Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455: 679-683.
15. Mestdagh P, Fredlund E, Pattyn F, et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 2010; 29: 1394-1404.
16. Weiss WA, Aldape K, Mohapatra G, et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985-2995.
17. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324-1334.
18. Gray JC, Kohler JA. Immunotherapy for neuroblastoma: Turning promise into reality. Pediatr Blood Cancer 2009; 53: 931-940.